More folic acid, the five questions: why, who, when, how much and how

被引:23
作者
Mastroiacovo, Pierpaolo [1 ]
Leoncini, Emanuele [1 ]
机构
[1] Alessandra Lisi Int Ctr Birth Defects & Prematur, I-00195 Rome, Italy
关键词
folic acid; folate status; neural tube defects; prevention; NEURAL-TUBE DEFECTS; CONGENITAL HEART-DEFECTS; FOLATE STATUS; FOOD FORTIFICATION; PLASMA FOLATE; SERUM FOLATE; MULTIVITAMIN SUPPLEMENTATION; HOMOCYSTEINE CONCENTRATIONS; MICROBIOLOGIC ASSAY; COLORECTAL ADENOMAS;
D O I
10.1002/biof.172
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In recent years, a number of studies have been performed to evaluate the possible health benefits of an increased intake of folic acid (FA) on human health. However, the only well-documented benefit emerging from randomized controlled trials, nonrandomized interventions trials, and observational studies is the risk reduction of neural tube defects (NTDs). NTDs are congenital malformations that include anencephaly, encephalocele, and spina bifida caused by the failure of fusion of the neural tube that normally closes between 22nd and 28th day since conception (on an average 40-42th day after the first day of last menstrual period). The occurrence of NTDs varies among population between 0.8 and 3 per 1,000, and it is estimated that 324,000 pregnancies are affected every year worldwide. More FA can decrease the NTDs risk up to 0.6 per 1,000 births. Other malformations as congenital heart defects, cleft lip, and limb deficiencies can be most probably also reduced. To decrease the NTDs risk, it is recommended that all women capable of becoming pregnant should have more FA. The goal is that every woman could start her pregnancy with an optimal folate status, estimated today to be as more than 906 nmol/L of red blood cell folate concentration. More FA can be obtained through a strict Mediterranean pattern of nutrition and healthy life style, fortified food, supplements. Women and health authorities can choose the most appropriate strategy. Monitoring folate status of women during the periconceptional period is an essential way to evaluate the success of the preferred strategy.
引用
收藏
页码:272 / 279
页数:8
相关论文
共 38 条
[21]   Inferior Vena Cava Filters Why, Who, and for How Long? [J].
Holly, Brian P. ;
Funaki, Brian ;
Lessne, Mark L. .
CLINICS IN CHEST MEDICINE, 2018, 39 (03) :645-+
[22]   The relationship between awareness and supplementation: Which Canadian women know about folic acid and how does that translate into use? [J].
Nelson, Chantal R. M. ;
Leon, Juan Andres ;
Evans, Jane .
CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2014, 105 (01) :E40-E46
[23]   Calcium Scoring for Cardiovascular Computed Tomography: How, When and Why? [J].
Carr, John Jeffrey .
RADIOLOGIC CLINICS OF NORTH AMERICA, 2019, 57 (01) :1-+
[24]   Introducing the Patient Safety Professional: Why, What, Who, How, and Where? [J].
Saint, Sanjay ;
Krein, Sarah L. ;
Manojlovich, Milisa ;
Kowalski, Christine P. ;
Zawol, Debbie ;
Shojania, Kaveh G. .
JOURNAL OF PATIENT SAFETY, 2011, 7 (04) :175-180
[25]   Follow-up of intestinal metaplasia in the stomach: When, how and why [J].
Angelo Zullo ;
Cesare Hassan ;
Adriana Romiti ;
Michela Giusto ;
Carmine Guerriero ;
Roberto Lorenzetti ;
Salvatore MA Campo ;
Silverio Tomao .
World Journal of Gastrointestinal Oncology, 2012, (03) :30-36
[26]   Follow-up of intestinal metaplasia in the stomach: When, how and why [J].
Zullo, Angelo ;
Hassan, Cesare ;
Romiti, Adriana ;
Giusto, Michela ;
Guerriero, Carmine ;
Lorenzetti, Roberto ;
Campo, Salvatore M. A. ;
Tomao, Silverio .
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2012, 4 (03) :30-36
[27]   Screening for meticillin resistant Staphylococcus aureus (MRSA): who, when, and how? [J].
Coia, John E. ;
Leanord, Alistair T. ;
Reilly, Jacqui .
BMJ-BRITISH MEDICAL JOURNAL, 2014, 348
[28]   Retinoids in the chemoprevention of non-melanoma skin cancers: why, when and how [J].
Bettoli, Vincenzo ;
Zauli, Stefania ;
Virgili, Anna .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2013, 24 (03) :235-237
[29]   Evaluation of genetic tests for susceptibility to common complex diseases: why, when and how? [J].
Wright, Caroline Fiona ;
Kroese, Mark .
HUMAN GENETICS, 2010, 127 (02) :125-134
[30]   Low molecular weight heparin in surgical valve procedures: When and how much for an optimal prophylaxis? [J].
Czerwinska-Jelonkiewicz, Katarzyna ;
Cisowski, Marek ;
Bochenek, Andrzej ;
Buszman, Piotr ;
Milewski, Krzysztof ;
Kunik, Piotr ;
Mularska, Magdalena ;
Kocot, Krzysztof ;
Politowski, Piotr ;
Braczkowski, Jakub ;
Trznadel, Agata ;
Aboodi, Michael S. ;
Buszman, Pawel .
CARDIOLOGY JOURNAL, 2020, 27 (05) :548-557